AstraZeneca

AZD1222 US Phase III Trial

The AstraZeneca’s AZD1222 US Phase III Trial demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease…